DUBLIN, Oct. 11, 2021 /PRNewswire/ — The "COVID-19 – Pipeline Insight, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
This "COVID-19 – Pipeline Insight, 2021" report provides comprehensive insights about 400+ companies and 400+ pipeline drugs in COVID-19 pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The companies and academics are working to assess challenges and seek opportunities that could influence COVID-19 R&D. The therapies under development are focused on novel approaches to treat/improve COVID-19.
COVID-19 Emerging Drugs Chapters
This segment of the COVID-19 report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
COVID-19 Emerging Drugs
REGN-COV2: Regeneron Pharmaceuticals
REGN-COV2 Antibody Cocktail (Casirivimab and Imdevimab; REGN10933 + REGN10987) is a combination of two monoclonal antibodies (REGN10933 and REGN10987) and was designed specifically to block infectivity of SARS-CoV-2, the virus that causes COVID-19.
To develop REGN-COV2, Regeneron scientists evaluated thousands of fully-human antibodies produced by the company's VelocImmune mice, which have been genetically modified to have a human immune system, as well as antibodies identified from humans who have recovered from COVID-19. The two potent, virus-neutralizing antibodies that form REGN-COV2 bind non-competitively to the critical receptor binding domain of the virus's spike protein, which diminishes the ability of mutant viruses to escape treatment and protects against spike variants that have arisen in the human population.
Bucillamine: Revive Therapeutics
Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC.2 The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via increasing glutathione activity and other antioxidant and anti-inflammatory activity, to lessen the destructive consequences of SARS-CoV2 infection in the lungs and attenuate the clinical course of COVID-19.
Mupadolimab (CPI-006): Corvus Pharmaceuticals
Mupadolimab (CPI-006) is an antibody that possesses dual properties: binding to CD73, which may reduce its suppression of the immune response via the adenosine pathway; and activating B cells, which may result in increased antibody production to antigens and the generation of memory B cells to extend protection.
VERU-111: Veru Inc.
Sabizabulin is a cytoskeleton disruptor which by causing microtubule depolymerization has both anti-viral and anti-inflammatory activity and could be effective against the SARS-CoV-2 virus by disrupting its intracellular transport along the microtubules. Microtubule trafficking is critical for viruses to be transported, replicated, assembled, and released from the cell. In addition, microtubule depolymerization drugs that target the "colchicine binding site" of microtubules, like sabizabulin, also have strong anti-inflammatory effects, including the potential to treat the cytokine release syndrome (cytokine storm) and septic shock induced by the SARS-CoV-2 viral infection that is associated with high COVID-19 mortality rates.
Sarconeos (BIO101): Biophytis
Sarconeos (BIO101) is an orally administered small molecule in development for the treatment of neuromuscular diseases. Based on results from cellular and animal studies, it is believed that Sarconeos (BIO101) stimulates biological resilience through activation of the MAS receptor and may have the potential to improve muscle function and preserve strength, mobility and respiratory capacity in various age-related and muscular wasting conditions.
Leronlimab is a humanized monoclonal antibody targeted against the CCR5 receptor found on T lymphocytes of the human immune system. It is being investigated as a potential therapy in the treatment of COVID-19 infection.
Tocilizumab: Hoffmann-La Roche
Actemra/RoActemra (Tocilizumab) is being developed by Hoffmann-La Roche in phase III stage of development for the treatment of Severe COVID-19 Pneumonia. Actemra/RoActemra is an anti-IL-6 receptor biologic approved to treat moderate-to-severe active rheumatoid arthritis (RA) in adults. The IL-6 protein triggers the body's immune and inflammatory response to fight infections. But, in the case of those patients where their immune system overreacts, inhibiting IL-6 could keep the body from attacking itself.
In Mar 2020, Roche received Chinese approval for the use of the drug to treat patients developing severe complications from Covid-19.
The new randomized, double-blind, placebo-controlled Phase III trial will be conducted in alliance with the US Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA). It will assess the safety and efficacy of Actemra in combination with standard of care compared to placebo.
COVID-19: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses COVID-19 therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging COVID-19 drugs.
Key Questions Answered
How many companies are developing COVID-19 drugs?
How many COVID-19 drugs are developed by each company?
How many emerging drugs are in mid-stage, and late-stage of development for the treatment of COVID-19?
What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the COVID-19 therapeutics?
What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
What are the clinical studies going on for COVID-19 and their status?
What are the key designations that have been granted to the emerging drugs?
Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A.
Syntax for Science, S.L
Notitia Biotechnologies Company
Grifols Therapeutics LLC
Grifols Therapeutics LLC
Chiesi Farmaceutici S.p.A.
Cadila Healthcare Limited
Organicell Regenerative Medicine
Natureceuticals Sdn Bhd
Bausch Health Americas
T3 solution for injection
Convalescent anti-SARS-CoV-2 MBT Plasma
Pegylated interferon lambda
Poractant alfa (Curosurf)
Povidine iodine nasal swabs
COVID-19 Therapeutic Biologics – Spike-GM-CSF Protein Lactated Ringer's Injection
Partially HLA-matched SARS-CoVSTs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/gcj0rs
Research and Markets
Laura Wood, Senior Manager
For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716
View original content:https://www.prnewswire.com/news-releases/global-covid-19-pipeline-report-2021—comprehensive-insights-about-400-companies-and-400-pipeline-drugs-301396942.html
SOURCE Research and Markets
Late last month, Pfizer (NYSE: PFE) announced that its drug, abrocitinib, was approved by Japan's Ministry of Health, Labour and Welfare (MHLW) as a treatment for patients 12 years old and up with moderate to severe atopic dermatitis or eczema. Japan's regulatory approval of abrocitinib under its trade name of Cibinqo came just weeks after approval by the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) for adults and adolescents with moderate to severe eczema. Let's dig into why the MHLW approved the drug for its eczema indication, as well as its sales potential and what it means for Pfizer.
Moderna's (NASDAQ: MRNA) stock has seen better days. Shares of the coronavirus vaccine giant have dropped 30% over the past month. Now, investors have turned their attention to something else: A regulatory meeting that could determine whether Moderna's booster candidate reaches the market in the coming days.
The U.S. Food and Drug Administration (FDA) granted approval for the company's autoimmune drug, avacopan, which instantly led to shares of ChemoCentryx more than doubling in value. For investors who didn't want to take on the risk heading into the FDA decision, the obvious question now is whether it's too late to invest in the healthcare stock. After amassing such impressive returns over a short time frame, can investors who buy the stock today still expect to earn a good return on their investment?
Shares of Regeneron Pharmaceuticals Inc. gained 2.7% in premarket trading on Thursday after the company said the Food and Drug Administration accepted its application for approval of its monoclonal antibody treatment for non-hospitalized COVID-19 patients and as a prophylaxis for some people who have been exposed to the virus. The FDA said it will decide whether to approve the therapy by April 13 based on the priority review designation it granted to the application. It plans to hold an advisory
Analysts were split Wednesday as they compared Crispr's gene-edited cancer drug to Allogene's — but CRSP stock tumbled as ALLO stock popped.
During October, many Americans acknowledge breast cancer awareness month in an effort to fight this horrible disease. It is the second-leading cancer among women, behind lung cancer. In a relentless effort to overcome this challenge, the medical community and pharmaceutical companies are heavily involved in the investigation, development, and production of treatments that could save the lives of millions.
Is AbbVie stock a buy as shares make a comeback on promising news for its drugs, Skyrizi and Rinvoq, in inflammatory conditions?
People who got Johnson & Johnson Inc’s COVID-19 vaccine as a first shot had a stronger immune response when boosted with vaccines from Pfizer Inc /BioNTech SE or Moderna Inc, a study run by the National Institutes of Health showed on Wednesday. The study, which is preliminary and hasn't been peer reviewed, is the latest challenge to J&J's efforts to use its COVID-19 vaccine as a booster in the United States. The study, which included more than 450 adults who received initial shots from Pfizer, Moderna, or Johnson & Johnson, showed that "mixing and matching" booster shots of different types is safe in adults.
Take action instead of just crossing off the days until you turn 65.
What happened Shares of the messenger RNA specialist Moderna (NASDAQ: MRNA) were up by a noteworthy 4% as of 12:35 p.m. EDT on Wednesday. While that percentage may not seem like a lot in absolute terms, it actually translates into a whopping $6 billion rise in the biotech's market capitalization.
Investors aren't impressed with the early-stage results from the biotech's lead cancer therapy candidate.
(Bloomberg) — Crispr Therapeutics AG plunged 8.8% in postmarket trading Tuesday after an experimental blood cancer therapy disappointed investors. That may spell more bad news for a Cathie Wood fund that’s already slid more than 20% this year.Most Read from BloombergHow France Turned the Humble Roundabout Into a Showcase for ArtWhat the Front Line of the U.S. Abortion Fight in Kentucky Looks Like NowWhat Comes After GE’s 129 Years of Greenhouse GasThey Invented the Must-Have Instrument for the
The monoclonal antibody therapy, which is marketed under the name REGEN-COV, is currently available under an emergency-use authorization.
The FDA authorized marketing of the first e-cigarette products, and several others are under review.
Federal health regulators cautioned that data was limited and that they had to rely on Johnson & Johnson’s own analysis for some of the study findings, rather than conducting their own.
Penny stocks, defined as equities with share prices under $5, are ultra-risky investing vehicles. Companies with super-low share prices are often in financial peril, have a bad habit of excessively diluting shareholders, or (more plainly) their products simply don't sell very well. Healthcare penny stocks, however, can fall under a completely different umbrella than the typical low-priced equity.
Giving people a different COVID-19 booster than the vaccine series that they originally received is safe and generates an immune response that is stronger, according to a
Citi Research looks into safety concerns about Merck's antiviral molnupiravir, and says the drug should still get approved by the Food and Drug Administration.
Investing in biotech companies can be hard to figure out. Great science and early-stage success doesn't always translate into drug approvals. In fact, only 10% of drug candidates that enter phase 1 trials will make it to the market.
Senator criticises CDC advice and lists alternative therapies for dealing with coronavirus on social media